Rivian's Delivery Momentum Fails to Break Range as Investors Await Margin Proof

What happened

Rivian has traded in a sideways range for much of the past year despite raising its 2026 delivery forecast to 65,000-70,000 units and reporting stronger Q2 deliveries. The recent commentary focuses on whether rising delivery forecasts can re-rate the stock, but the market has not responded because unit growth alone does not address persistent margin and funding concerns. Our latest master report shows that while Q2 automotive gross loss narrowed to $(36)M, the quarter still included about $100M of R2 ramp costs and lower average selling prices from a higher mix of vans and R2. The company raised roughly $1.3B net in July at $15.50 but still states it will require additional financings in the near and long term. The article adds little new information; the real catalysts for a sustained move are automotive gross margin inflection and the draw of the $1.0B Volkswagen loan in October, not delivery beats.

Implication

The current stock price already reflects a smooth R2 ramp and delivery growth, so the upside is limited unless Rivian demonstrates automotive gross loss narrowing and converts conditional funding into cash. The next 90 days hold three checkpoints: Q3 delivery pace against the 65,000-70,000 guide, Q3-Q4 automotive gross profit trend, and the October 1-30 window to draw the $1.0B Volkswagen loan. If those checkpoints show progress, the stock can re-rate toward $18.50 or higher, but a failure on any front could push it toward the $13 attractive entry or below. We recommend patience; accumulating near $13 with a stop-loss below $11 is more prudent than chasing the current range. However, if Q3 margin improves and the loan is drawn, a rapid re-rating may occur, so monitor closely for early signals.

Thesis delta

The news article does not materially change our thesis; it underscores the market's fixation on delivery forecasts while our analysis emphasizes margin quality and financing risk. We maintain a WAIT rating with conviction 4 and see the stock remaining rangebound between $13 and $18.50 until clear catalysts emerge. A slight negative nuance is added: if the market continues to overweight deliveries and ignore balance sheet risks, the stock may stay in the range longer than our base case assumes.